TABLE 2.

Characteristics of laboratory-derived mutants of S. aureus ATCC 29213 and resistant S. aureus clinical isolates

Strain	MIC (μg/ml)a							TDc (min)	Mutation(s) in QRDR encoded byb:
	Compound 1	Compound 2	Compound 3	CIP	MOX	GEM	EB		gyrA	grlA
ATCC 29213	0.004	0.004	0.008	0.25	0.06	0.03	4	30
ACH-0204	0.016	0.016	0.03	0.5	0.125	0.125	4	30	Ser84Leu
ACH-0206	0.015	0.015	0.03	0.5	0.125	0.125	4	30	Ser84Leu
ACH-0221	0.03	0.03	0.03	1	0.5	0.5	16	ND	Ser84Leu
ACH-0216	0.008	0.008	0.016	2	0.25	0.125	4	30		Ser80Phe
ACH-0218	0.008	0.004	0.08	2	0.25	0.125	16	ND		Glu84Lys
ACH-0126	0.125	0.125	0.5	64	4	4	4	34	Ser84Leu	Ser80Phe
ACH-0210	0.125	0.125	0.5	64	4	4	2	30	Ser84Leu	Ser80Phe
ACH-0186	0.5	0.25	0.5	64	16	4	1	34	Ser84Leu	Ser80Phe, Ala116Val
ACH-0192	0.5	1	2	64	16	8	2	121	Ser84Leu	Ser80Phe, Ala116Val
ACH-0203	1	1	2	128	32	32	32	338	Ser84Leu	Ser80Phe, Ala116Val
ACH-0129	0.5	0.5	4	64	8	8	4	40	Ser84Leu, Glu88Val	Ser80Phe, Ala116Val
ACH-0130	1	1	8	256	32	32	32	52	Ser84Leu, Glu88Val	Ser80Phe, Ala116Val
ACH-0201	2	1	8	64	16	8	2	180	Ser84Leu, Glu88Val	Ser80Phe, Ala116Val
ACH-0141	2	2	16	64	16	4	4	340	Ser84Leu, Glu88Val	Ser80Phe, Ala116Val
ATCC 33591	0.004	0.004	0.004	0.5	0.125	0.06	16	ND
NY2746	0.25	0.25	0.5	256	8	32	16	33	Ser84Leu	Ser80Phe
ATCC 700699	0.25	0.125	0.25	64	4	4	>64	39	Ser84Leu, Glu409Lys	Ser80Phe
BSA643	0.125	0.125	0.25	256	16	32	16	38	Ser84Leu	Ser80Tyr, Glu84Gly
BSA678	0.5	0.5	4	128	>64	64	4	42	Ser84Leu, Ser85Pro	Ser80Phe, Glu84Lys
ACH-0231	2	1	16	>64	32	>64	16	35	Ser84Leu, Glu88Lys	Ser80Tyr, Glu84Gly

^aCIP, ciprofloxacin; GEM, gemifloxacin; MOX, moxifloxacin; EB, ethidium bromide.

^bNo mutations found in gyrB or grlB (parE).

^cT_D, doubling time of bacterial growth.